Amano Y - Search Results

1

Antidyslipidemic effects of a farnesoid X receptor antagonist in primates.

Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Life Sci. 2014 Jun 13;106(1-2):25-31. doi: 10.1016/j.lfs.2014.04.019. Epub 2014 Apr 29. Life Sci. 2014. PMID: 24787893

2

Effects of a farnesoid X receptor antagonist on hepatic lipid metabolism in primates.

Amano Y, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Eur J Pharmacol. 2014 Jan 15;723:108-15. doi: 10.1016/j.ejphar.2013.10.048. Epub 2013 Dec 19. Eur J Pharmacol. 2014. PMID: 24361308

3

Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.

Amano Y, Ishikawa E, Shinozawa E, Shimada M, Miura S, Adachi R, Tozawa R. Amano Y, et al. Life Sci. 2014 Jul 11;108(1):7-12. doi: 10.1016/j.lfs.2014.04.029. Epub 2014 May 5. Life Sci. 2014. PMID: 24805868

4

Farnesoid X receptor antagonist exacerbates dyslipidemia in mice.

Amano Y, Yamakawa H, Yonemori K, Shimada M, Tozawa R. Amano Y, et al. Pharmacol Rep. 2018 Feb;70(1):172-177. doi: 10.1016/j.pharep.2017.07.010. Epub 2017 Jul 15. Pharmacol Rep. 2018. PMID: 29367104

5

Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.

Shinozawa E, Amano Y, Yamakawa H, Haba M, Shimada M, Tozawa R. Shinozawa E, et al. Among authors: amano y. Pharmacol Res Perspect. 2018 Mar 8;6(2):e00390. doi: 10.1002/prp2.390. eCollection 2018 Apr. Pharmacol Res Perspect. 2018. PMID: 29541476 Free PMC article.

6

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y. Nishimoto T, et al. Among authors: amano y. Br J Pharmacol. 2003 Jul;139(5):911-8. doi: 10.1038/sj.bjp.0705332. Br J Pharmacol. 2003. PMID: 12839864 Free PMC article.

7

Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes.

Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Nishimoto T, et al. Among authors: amano y. Biochem Pharmacol. 2003 Dec 1;66(11):2133-9. doi: 10.1016/j.bcp.2003.08.011. Biochem Pharmacol. 2003. PMID: 14609738

8

Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge.

Amano Y, Shimizu F, Yasuno H, Harada A, Tsuchiya S, Isono O, Nagabukuro H, Tozawa R. Amano Y, et al. Hepatol Res. 2017 Jan;47(1):103-115. doi: 10.1111/hepr.12709. Epub 2016 May 11. Hepatol Res. 2017. PMID: 26992446

9

Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice.

Tsuchiya S, Amano Y, Isono O, Imai M, Shimizu F, Asada M, Imai S, Harada A, Yasuhara Y, Tozawa R, Nagabukuro H. Tsuchiya S, et al. Among authors: amano y. Hepatol Res. 2017 May;47(6):584-592. doi: 10.1111/hepr.12773. Epub 2016 Aug 17. Hepatol Res. 2017. PMID: 27421062

10

Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.

Morimoto M, Amano Y, Oka M, Harada A, Fujita H, Hikichi Y, Tozawa R, Yamaoka M, Hara T. Morimoto M, et al. Among authors: amano y. PLoS One. 2017 Dec 7;12(12):e0189480. doi: 10.1371/journal.pone.0189480. eCollection 2017. PLoS One. 2017. PMID: 29216311 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

923 results

Search Page

Filters